Cargando…

+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications

Background: Alterations of the insulin-like growth factor (IGF) pathway along with genetic variations of the IGF1 receptor (IGF1R) gene have been linked to the development of systemic autoimmunity, possibly through apoptosis induction. This study aims to investigate whether genetic variations of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Skarlis, Charalampos, Marketos, Nikolaos, Nezos, Adrianos, Papanikolaou, Asimina, Voulgarelis, Michael, Koutsilieris, Michael, Moutsopoulos, Haralampos M., Mavragani, Clio P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432056/
https://www.ncbi.nlm.nih.gov/pubmed/34501407
http://dx.doi.org/10.3390/jcm10173960
_version_ 1783751075151478784
author Skarlis, Charalampos
Marketos, Nikolaos
Nezos, Adrianos
Papanikolaou, Asimina
Voulgarelis, Michael
Koutsilieris, Michael
Moutsopoulos, Haralampos M.
Mavragani, Clio P.
author_facet Skarlis, Charalampos
Marketos, Nikolaos
Nezos, Adrianos
Papanikolaou, Asimina
Voulgarelis, Michael
Koutsilieris, Michael
Moutsopoulos, Haralampos M.
Mavragani, Clio P.
author_sort Skarlis, Charalampos
collection PubMed
description Background: Alterations of the insulin-like growth factor (IGF) pathway along with genetic variations of the IGF1 receptor (IGF1R) gene have been linked to the development of systemic autoimmunity, possibly through apoptosis induction. This study aims to investigate whether genetic variations of the IGF1R contribute to Sjögren’s syndrome (SS) pathogenesis and explores potential functional implications. Methods: DNA extracted from whole peripheral blood derived from 277 primary SS patients, complicated or not by lymphoma, and 337 Healthy controls (HC) was genotyped for the rs2229765 IGF1R polymorphism using the RFLP-PCR assay. Gene expression of IGF1R and IGF1 isoforms, caspases 1, 4, and 5, and inflammasome components NLRP3, ASC, IL1β, IL18, IL33, IGFBP3, and IGFBP6 were quantitated by RT-PCR in total RNA extracted from minor salivary gland biopsies (MSGs) of 50 SS patients and 13 sicca controls (SCs). In addition, IGF1R immunohistochemical (IHC) expression was assessed in formalin-fixed, paraffin-embedded MSG tissue sections derived from 10 SS patients and 5 SCs. Results: The prevalence of the A/A genotype of the rs2229765 IGF1R polymorphism was significantly higher in the anti-Ro/SSA positive SS population compared to healthy controls (24.8% vs. 10.7%, p = 0.001). Moreover, IGF1Rs at both mRNA and protein levels were reduced in SS-derived MSGs compared to SCs and were negatively associated with caspase 1 transcripts. The latter were positively correlated with NLRP3, ASC, and IL1β at the salivary gland tissue level. IGF1R expression in peripheral blood was negatively correlated with ESR and IgG serum levels and positively correlated with urine-specific gravity values. Conclusions: The rs2229765 IGF1R variant confers increased susceptibility for seropositive primary SS. Dampened IGF1R mRNA and protein expression in salivary gland tissues could be related to increased apoptosis and subsequently to the activation of inflammasome pathways.
format Online
Article
Text
id pubmed-8432056
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84320562021-09-11 +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications Skarlis, Charalampos Marketos, Nikolaos Nezos, Adrianos Papanikolaou, Asimina Voulgarelis, Michael Koutsilieris, Michael Moutsopoulos, Haralampos M. Mavragani, Clio P. J Clin Med Article Background: Alterations of the insulin-like growth factor (IGF) pathway along with genetic variations of the IGF1 receptor (IGF1R) gene have been linked to the development of systemic autoimmunity, possibly through apoptosis induction. This study aims to investigate whether genetic variations of the IGF1R contribute to Sjögren’s syndrome (SS) pathogenesis and explores potential functional implications. Methods: DNA extracted from whole peripheral blood derived from 277 primary SS patients, complicated or not by lymphoma, and 337 Healthy controls (HC) was genotyped for the rs2229765 IGF1R polymorphism using the RFLP-PCR assay. Gene expression of IGF1R and IGF1 isoforms, caspases 1, 4, and 5, and inflammasome components NLRP3, ASC, IL1β, IL18, IL33, IGFBP3, and IGFBP6 were quantitated by RT-PCR in total RNA extracted from minor salivary gland biopsies (MSGs) of 50 SS patients and 13 sicca controls (SCs). In addition, IGF1R immunohistochemical (IHC) expression was assessed in formalin-fixed, paraffin-embedded MSG tissue sections derived from 10 SS patients and 5 SCs. Results: The prevalence of the A/A genotype of the rs2229765 IGF1R polymorphism was significantly higher in the anti-Ro/SSA positive SS population compared to healthy controls (24.8% vs. 10.7%, p = 0.001). Moreover, IGF1Rs at both mRNA and protein levels were reduced in SS-derived MSGs compared to SCs and were negatively associated with caspase 1 transcripts. The latter were positively correlated with NLRP3, ASC, and IL1β at the salivary gland tissue level. IGF1R expression in peripheral blood was negatively correlated with ESR and IgG serum levels and positively correlated with urine-specific gravity values. Conclusions: The rs2229765 IGF1R variant confers increased susceptibility for seropositive primary SS. Dampened IGF1R mRNA and protein expression in salivary gland tissues could be related to increased apoptosis and subsequently to the activation of inflammasome pathways. MDPI 2021-08-31 /pmc/articles/PMC8432056/ /pubmed/34501407 http://dx.doi.org/10.3390/jcm10173960 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skarlis, Charalampos
Marketos, Nikolaos
Nezos, Adrianos
Papanikolaou, Asimina
Voulgarelis, Michael
Koutsilieris, Michael
Moutsopoulos, Haralampos M.
Mavragani, Clio P.
+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title_full +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title_fullStr +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title_full_unstemmed +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title_short +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications
title_sort +3179g/a insulin-like growth factor-1 receptor polymorphism: a novel susceptibility contributor in anti-ro/ssa positive patients with sjögren’s syndrome: potential clinical and pathogenetic implications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432056/
https://www.ncbi.nlm.nih.gov/pubmed/34501407
http://dx.doi.org/10.3390/jcm10173960
work_keys_str_mv AT skarlischaralampos 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT marketosnikolaos 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT nezosadrianos 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT papanikolaouasimina 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT voulgarelismichael 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT koutsilierismichael 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT moutsopoulosharalamposm 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications
AT mavraganicliop 3179gainsulinlikegrowthfactor1receptorpolymorphismanovelsusceptibilitycontributorinantirossapositivepatientswithsjogrenssyndromepotentialclinicalandpathogeneticimplications